Samantha Bannister1, Eva Sudbury1, Paola Villanueva1, Kirsten Perrett2, Nigel Curtis3. 1. Department of Paediatrics, The University of Melbourne, Parkville, Victoria, Australia; Infectious Diseases Research Group, Murdoch Children's Research Institute, Parkville, Victoria, Australia; Infectious Diseases Unit, Royal Children's Hospital Melbourne, Parkville, Victoria, Australia. 2. Department of Paediatrics, The University of Melbourne, Parkville, Victoria, Australia; Population Allergy Group, Murdoch Children's Research Institute, Parkville, Victoria, Australia; Department of Allergy and Immunology, Royal Children's Hospital Melbourne, Parkville, Victoria, Australia. 3. Department of Paediatrics, The University of Melbourne, Parkville, Victoria, Australia; Infectious Diseases Research Group, Murdoch Children's Research Institute, Parkville, Victoria, Australia; Infectious Diseases Unit, Royal Children's Hospital Melbourne, Parkville, Victoria, Australia. Electronic address: nigel.curtis@rch.org.au.
Abstract
INTRODUCTION: Revaccination with Bacillus Calmette-Guérin (BCG) vaccine is not generally recommended due to a lack of proven efficacy of repeat doses for protection against tuberculosis. However, there is a growing interest in the use of BCG vaccine for its 'off-target' effects which might involve revaccination. We did a systematic review of the safety of BCG revaccination. METHODS: MEDLINE (1946 to March 2020) and the BCG World Atlas (updated 2017) were searched, limiting to studies of BCG administration by the intradermal or percutaneous route. Adverse events as well as patient and vaccine characteristics were reviewed. RESULTS: The search identified 388 articles, of which 24 met the inclusion criteria. These reported 22 studies comprising eight randomised trials, four case-control studies, four observational studies and six case series or reports. Overall, there was evidence for a small increase in the rate of mild local and systemic reactions. No serious adverse events were reported in immunocompetent individuals. CONCLUSIONS: Evidence to date suggests that revaccination with BCG vaccine carries minimal risk. Future studies of BCG vaccine for novel applications should report adverse event data stratified by prior BCG vaccination status.
INTRODUCTION: Revaccination with Bacillus Calmette-Guérin (BCG) vaccine is not generally recommended due to a lack of proven efficacy of repeat doses for protection against tuberculosis. However, there is a growing interest in the use of BCG vaccine for its 'off-target' effects which might involve revaccination. We did a systematic review of the safety of BCG revaccination. METHODS: MEDLINE (1946 to March 2020) and the BCG World Atlas (updated 2017) were searched, limiting to studies of BCG administration by the intradermal or percutaneous route. Adverse events as well as patient and vaccine characteristics were reviewed. RESULTS: The search identified 388 articles, of which 24 met the inclusion criteria. These reported 22 studies comprising eight randomised trials, four case-control studies, four observational studies and six case series or reports. Overall, there was evidence for a small increase in the rate of mild local and systemic reactions. No serious adverse events were reported in immunocompetent individuals. CONCLUSIONS: Evidence to date suggests that revaccination with BCG vaccine carries minimal risk. Future studies of BCG vaccine for novel applications should report adverse event data stratified by prior BCG vaccination status.
Authors: Mehrsa Jalalizadeh; Keini Buosi; Franciele A V Dionato; Luciana S B Dal Col; Cristiane F Giacomelli; Karen L Ferrari; Ana Carolina Pagliarone; Patrícia A F Leme; Cristiane L Maia; Reza Yadollahvandmiandoab; Quoc-Dien Trinh; Kleber G Franchini; Marcio C Bajgelman; Leonardo O Reis Journal: J Intern Med Date: 2022-06-03 Impact factor: 13.068
Authors: Franciele A V Dionato; Mehrsa Jalalizadeh; Keini Buosi; Marília B Visacri; Luciana S B Dal Col; Cristiane F Giacomelli; Patricia A F Leme; Cristiane L Maia; Patricia Moriel; Leonardo O Reis Journal: Vaccine Date: 2022-06-20 Impact factor: 4.169